Ajanta Pharma Reports 31% Rise in Q1 Profit on Strong India and US Sales
Ajanta Pharma Ltd reported a 31% increase in profit after tax to Rs 334 crore for the first quarter ending June 30, up from Rs 255 crore in the same period last year. Revenue from operations rose 25% to Rs 1,626 crore. Growth was driven by a 24% rise in branded generics revenue in India to Rs 509 crore and a 57% increase in US generic revenue to Rs 487 crore, according to the company's regulatory filing.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 36/100.
Outlets measured: businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 30 Jul, 09:31 am. Other outlets followed.
- 1